PROVENTION BIO, INC. ETFs positioned on Provention Bio, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 509 M€ | -.--% | ||
| 0.00% | 9 M€ | +5.94% | - | |
| 0.00% | 147 M€ | +5.02% | - | |
| 0.00% | 18 M€ | +3.48% | - |
Provention Bio, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing the development and commercialization of investigational therapies that intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes TZIELD (teplizumab-mzwv), PRV-3279, Ordesekimab and PRV-101. TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of stage three T1D in adults and pediatric patients aged eight years and older with stage two T1D. It is also developing TZIELD for use in stage three newly diagnosed T1D patients. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics. Ordesekimab is a human anti-interleukin 15 (IL-15) monoclonal antibody for the treatment of gluten-free diet non-responsive celiac disease. PRV-101 is a CVB vaccine to prevent acute CVB infections.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -2.86% | 87.37B | |
| +4.08% | 41.01B | |
| -25.35% | 28.08B | |
| +54.25% | 24.72B | |
| -4.52% | 17.47B | |
| -42.09% | 11.69B | |
| -17.77% | 11.6B | |
| -12.10% | 11.56B | |
| +1.65% | 8.44B |
